CN1823973A - Liquid capsule for treating gynecophthy inflammation and its preparation method - Google Patents
Liquid capsule for treating gynecophthy inflammation and its preparation method Download PDFInfo
- Publication number
- CN1823973A CN1823973A CN 200510120555 CN200510120555A CN1823973A CN 1823973 A CN1823973 A CN 1823973A CN 200510120555 CN200510120555 CN 200510120555 CN 200510120555 A CN200510120555 A CN 200510120555A CN 1823973 A CN1823973 A CN 1823973A
- Authority
- CN
- China
- Prior art keywords
- liquid capsule
- extractum
- group
- filtrate
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A liquid soft capsule for treating the gynecologic inflammation is prepared from the Chinese-medicinal extract powder prepared from 6 Chinese-medicinal extract powder prepared from 6 Chinese-medicinal materials including spatholobus stem, cherokee rose root, flemingia root, green chiretta, etc, the suspending aid chosen from beeswax, lecithin, aluminum monostearate, and ethyl cellulose, and the dispersing agent chosen from soybean oil, sesame oil, peanut oil, rapeseed oil, etc.
Description
Technical field
The present invention relates to a kind of herb liquid body capsule, relate in particular to a kind of liquid capsule for the treatment of gynecological inflammation and preparation method thereof.
Background technology
Existing market has a kind of Chinese patent medicine " JINJI JIAONANG " that is used for the treatment of gynecological inflammation, prescription consists of Caulis Spatholobi, Radix Rosae Laevigatae, Radix Flemingiae Philippinensis, Caulis Mahoniae, Radix Zanthoxyli and Herba Andrographis, the weight ratio of each flavour of a drug is: 30: 16: 16: 16: 6: 5, this medicine clinical application effect was better.But also there is following deficiency:
1, medicament contg inaccuracy, it is bigger to fluctuate;
2, the refining degree of medicine is low, and dose is big, needs every day and takes 12.
The technical process that retrieves " JINJI JIAONANG " in Chinese Pharmacopoeia Commission is: get Herba Andrographis 30g, be ground into fine powder, the five tastes such as residue Herba Andrographis and Radix Rosae Laevigatae decoct with water secondary, each 2.5 hours, collecting decoction filtered, filtrate is condensed into the thick paste shape, add above-mentioned fine powder, mixing, drying, pulverize, sieve, incapsulate, promptly.As seen, the medical material in the former technology has mainly adopted and has stayed powder and water to put forward two kinds of methods to handle, and these two kinds of methods are that refining degree is minimum in the present Chinese medicine extraction process for purification.Simultaneously, do not have concrete parameter in the literature method, thereby do not possess operability yet, want to solve above all deficiencies, just must the new extraction preparation method of redesign one cover.
Summary of the invention
The objective of the invention is to: at the problem that original product exists, in conjunction with characteristics of prescriptions and relevant medical literature data, the inventor has carried out systematic research, and the preparation method that initiative makes new advances can keep drug effect, can reduce dose again.This method has comprised following processing step:
The present invention realizes by following scheme: described liquid capsule is made up of by following weight proportion Chinese medical concrete powder, suspending agent and dispersant: 1: 0.05-0.15: 0.7-2.0.Described Chinese medical concrete powder by Caulis Spatholobi, Radix Rosae Laevigatae, Radix Flemingiae Philippinensis, Caulis Mahoniae, Radix Zanthoxyli and Herba Andrographis is by weight: 30: 16: 16: make at 16: 6: 5.
Suspending agent of the present invention can be one or more the mixture in Cera Flava, lecithin, aluminum monostearate, the ethyl cellulose, is preferably Cera Flava.Described dispersant vegetable oil can be one or more the mixture in soybean oil, Oleum sesami, Oleum Arachidis hypogaeae semen, Oleum Brassicae campestris and other edible plants oil, in view of soybean oil cheap, output big, stay in grade, so be decided to be optimum selection.
According to universal law, the amount of suspensoid (being the mixture of dispersant and suspending agent) is big more, the stability of suspension is just good more, yet in actual production, the amount of suspensoid is too big, can cause the increase of cost again, also make troubles for production process, therefore must on the basis that can reach stablizing effect, reduce the suspensoid consumption as far as possible, the inventor gropes through experiment, the optimum weight ratio of having determined medicated powder and Cera Flava, soybean oil is 1: 0.1: 1.4, can satisfy the requirement of stability so fully, has saved the consumption of suspensoid again.
The product of the original relatively technology of the resulting product of the present invention, more refining, the unit formulation drug loading increases, and content of dispersion is accurate, does not have bad abnormal smells from the patient, and patient's taking convenience has overcome the various drawbacks of original technical products substantially, has reached purpose of the present invention.
Preparation method of the present invention has comprised following processing step:
A. get Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 60%～80% ethanol of 6～10 times of amounts, extracts 2～3 times, each 1～2 hour, filter, merging filtrate reclaims ethanol, filters filtrate for later use; B. get Radix Rosae Laevigatae and Radix Flemingiae Philippinensis, add 6～10 times of water gagings, decoct 2～3 times, each 1～2 hour, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, relative density is 1.10～1.20 extractum when continuing to be concentrated into 60 ℃; D. with extract dry among the c, make fine powder; E. get suspending agent, dispersant, 60-70 ℃ of heat fused adds above-mentioned medicated powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
On above-mentioned technology basis, the inventor further works out preferential technical process:
A. get Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 70% ethanol of 8 times of amounts, extracts three times, each 2 hours, filter, merging filtrate reclaims ethanol to there not being the alcohol flavor, leaves standstill, and filters filtrate for later use; B. get Radix Rosae Laevigatae, Radix Flemingiae Philippinensis adds 8 times of water gagings, decocts secondary, and each 2 hours, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, mixing, relative density is 1.15～1.20 extractum when continuing to be concentrated into 60 ℃; D. extractum among the c is spray dried to fine powder; E. get 1 part of above-mentioned dried cream powder, 0.1 part of suspending agent, 1.4 parts of dispersants, suspending agent, dispersant 60-70 ℃ heat fused adds dried cream powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Through the pilot scale checking, above technical process is pratical and feasible, has reached inventor's initial purpose substantially.By technical process of the present invention extract refining after, final the rate of extract is 6～8%; And contrast experiment simultaneously shows, extracts purified the rate of extract by former process and has reached 15%.As seen, the process of the present invention's design has certain advance than former process, can obviously reduce to make total amount, thereby also reduce dose, has made things convenient for patient's use.
The specific embodiment
Come further to set forth specific implementation process of the present invention by the following examples.
Embodiment 1:
Get Caulis Spatholobi 30kg, Radix Rosae Laevigatae 16kg, Radix Flemingiae Philippinensis 16kg, Caulis Mahoniae 16kg, Radix Zanthoxyli 6kg, Herba Andrographis 5kg; Make according to the following steps again:
A. get Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 60% ethanol of 6 times of amounts, extracts 3 times, each 1 hour, filter, merging filtrate reclaims ethanol, filters filtrate for later use; B. get Radix Rosae Laevigatae and Radix Flemingiae Philippinensis, add 6 times of water gagings, decoct 2 times, each 1 hour, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, relative density is 1.10～1.15 extractum when continuing to be concentrated into 60 ℃; D. with extractum 60-80 ℃ drying under reduced pressure among the c, be ground into fine powder, cross 120 mesh sieves, get 5.6kg.E. get Semen Maydis oil 3.85kg, Cera Flava 0.3kg, 60-70 ℃ of heat fused adds above-mentioned medicated powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Embodiment 2:
Get Caulis Spatholobi 30kg, Radix Rosae Laevigatae 16kg, Radix Flemingiae Philippinensis 16kg, Caulis Mahoniae 16kg, Radix Zanthoxyli 6kg, Herba Andrographis 5kg; Make according to the following steps again:
A. get Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 80% ethanol of 10 times of amounts, extracts 2 times, each 1 hour, filter, merging filtrate reclaims ethanol, filters filtrate for later use; B. get Radix Rosae Laevigatae and Radix Flemingiae Philippinensis, add 6 times of water gagings, decoct 2 times, each 1 hour, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, relative density is 1.10～1.15 extractum when continuing to be concentrated into 60 ℃; D. with extractum spray drying among the c, get fine powder 5.5kg; E. get soybean oil 10kg, aluminum monostearate 0.7kg, 60-70 ℃ of heat fused adds above-mentioned medicated powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Embodiment 3:
Get Caulis Spatholobi 30kg, Radix Rosae Laevigatae 16kg, Radix Flemingiae Philippinensis 16kg, Caulis Mahoniae 16kg, Radix Zanthoxyli 6kg, Herba Andrographis 5kg; Make according to the following steps again:
A. get Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 70% ethanol of 8 times of amounts, extracts three times, each 2 hours, filter, merging filtrate reclaims ethanol to there not being the alcohol flavor, leaves standstill, and filters filtrate for later use;
B. get Radix Rosae Laevigatae, Radix Flemingiae Philippinensis adds 8 times of water gagings, decocts secondary, and each 2 hours, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, mixing, relative density is 1.15～1.20 extractum when continuing to be concentrated into 60 ℃; D. extractum among the c (170-190 ℃) is spray dried to fine powder 5.5kg; E. get Cera Flava 0.55kg, soybean oil 7.7kg, 60-70 ℃ of heat fused adds dried cream powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Embodiment 4:
Get vegetable oil 9kg, aluminum monostearate 620g, 60-70 ℃ of heat fused adds above-mentioned medicated powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Other are with embodiment 2.
After the present invention finishes technology contents,, also carried out pharmacodynamic study for proving its curative effect:
1, experiment material
1.1 animal
Rat: the SD kind, female, body weight 220 ± 20 grams; Male, body weight 160 ± 10 grams, SPF level; Mice: the ICR kind, male, body weight 20 ± 2 grams, SPF level.
1.2 medicine and reagent
Liquid capsule extract of the present invention: make by optimum process extraction of the present invention, every gram extract contains crude drug 15.7 grams.JINJI JIAONANG: commercially available.Ofloxacin: commercially available, every contains ofloxacin 200mg.Aspirin tablet: commercially available.The phenol rubber cement: liquefied phenol 5ml, tragacanth 1ml, glycerol 4g, adding distil water is to 20ml.
1.3 strain
Escherichia coli clinical separation strain, broth bouillon, eosin methylene blue agar: commercially available, the Pass Test standard.
1.4 instrument
BV-100 hemorheology tester.
2, method and result
2.1 influence to the pelvic inflammatory disease model
2.1.1 the inhibitory action of rat pelvic inflammatory disease model due to the coli-infection
[1]
Strain preparation: the escherichia coli after the mice of learning from else's experience is gone down to posterity join in the broth bouillon, cultivate 7 hours through 37 ℃ of incubators, get 0.1ml bacterium liquid and join in the 10ml nutrient broth medium, cultivated again 17 hours, with physiological saline solution nephelometer number, be diluted to 107/ml before using, standby.
Get rat with 0.3% pentobarbital sodium intraperitoneal injection of anesthesia, 1ml/Kg, fixedly animal, under aseptic condition, open abdomen, expose the uterus, left side, extract 0.2ml bacterium liquid, with syringe needle mechanical damage endometrial tissue, limit wearing and tearing marginal not is gone into 0.1ml bacterium liquid, injects remaining 0.1ml bacterium liquid then.Abdomen is closed in layering, sterilization art district.Sham operated rats is only opened abdomen, exposes the uterus, left side and is closed the abdomen operation, does not inject bacterium liquid.After the modeling 10 days, the animal except that sham operated rats is divided into model group, positive drug group, the large, medium and small dosage group of liquid capsule extract of the present invention, 10 every group at random.According to dosage difference gastric infusion in the following table, large, medium and small dosage is distinguished 15,7.5,3.75 times of suitable clinical dosage, successive administration 20 days, every day 1 time, the administration volume is 0.5ml/100g, sham operated rats and model group give consubstantiality hydrops, and the positive control drug group gives Ofloxacin, quite 10 times of clinical dosage.After the last administration 24 hours, animal with 0.3% pentobarbital sodium intraperitoneal injection of anesthesia, is cut open the belly, win the bilateral uterus, get endometrium liquid identify inoculation on the culture medium escherichia coli, put cultivate 24 hours in 37 ℃ of incubators after, check to have or not the escherichia coli length of all being born.After internal organs are removed fatty tissue, divide the weight of another name bilateral uterus and ovary with electronic balance.Difference with left and right sides uterus weight is the swelling degree, calculates the swelling rate.After weighing with uterus and ovary 10% formaldehyde fixed, paraffin embedding, conventional section, HE dyeing, light microscopic is observed the morphologic variation of uterus pathology down, according to grade scale, adopts SSPS software to add up the comparable group differences.
2.1.1.1 to colibacillary inhibitory action
Liquid capsule extract of the present invention administration is after 20 days, after model group rat endometrium liquid is inoculated in escherichia coli evaluation culture medium, cultivated 24 hours, still can detect escherichia coli, the recall rate of escherichia coli bacterium colony is 100%, sham operated rats all can't check escherichia coli, and is remarkable with the sham operated rats comparing difference.After positive drug group and administration three dosage group rat endometrium liquid were inoculated in escherichia coli evaluation culture medium, through cultivating, the recall rate of escherichia coli bacterium colony was 10-30%, and recall rate obviously descends.Prompting, liquid capsule extract of the present invention is to having certain inhibitory action in the coli-infection of body uterus.See Table 1.
The influence of table 1 pair bacillary pelvic inflammatory disease rat model endometrium escherichia coli recall rate
| Group | Dosage (the g crude drug/Kg) | Clump count (individual) | Recall rate (%) |
| Dosage group small dose group in the heavy dose of group of sham operated rats model control group ofloxacin group | 0.07 22.2 11.1 5.6 | 0 10 0 1 2 3 | 0 100 ## 0 * 10 * 20 * 30 * |
Annotate: rank test: compare ##P＜0.01 with sham operated rats; Compare * P＜0.05 with model group.
2.1.2 inhibitory action to non-specific rat pelvic inflammatory disease model
[2]
Get rat and be divided into the heavy dose of group of normal control group, model control group, positive drug control group and administration, middle dosage group, small dose group, 10 every group at random according to body weight.Except that the normal control group, all the other animals enter the vagina deep and inject 25% phenol rubber cement with special elongated shape irrigation stomach device, every 1.5ml, 3 days 1 time, totally 3 times.Large, medium and small dosage was distinguished 15,7.5,3.75 times of suitable clinical dosage, successive administration 12 days according to dosage difference gastric infusion in the table 2 in the 3rd day after the modeling.With the positive contrast medicine of JINJI JIAONANG, quite 40 times of clinical dosage.Every day 1 time, the administration volume is 0.5ml/100g.After time administration 1 hour, sodium pentobarbital anesthetized animal with 3%, abdominal aortic blood, measure hemorheology index, dissect and take out uterus and ovary observation and record finding of naked eye, the vagina of drawing materials is organized to uterus subangle place, put in 10% the formalin fixing, the back circulating water of drawing materials washes, the gradient ethanol dehydration, and dimethylbenzene is transparent, to organize after 3 days and vertically cut from center line, the waxdip embedding, section, HE dyeing, the optical resin mounting, light microscopic is observed the vagina of each treated animal down to uterine cancer cell morphological change and mucosa, the morphologic inflammation of matter changes degree between under the mucosa, adds up the comparable group differences according to grade scale.
2.1.2.1 to hemorheological influence
With the normal control group relatively, the model group rat shear rate be 94.5 and 0.945 o'clock whole blood viscosity all normally control rats obvious rising is arranged, but packed cell volume and plasma viscosity are not had obvious influence.Positive drug and the big or middle dosage group of liquid capsule extract of the present invention rat shear rate be 94.5 and 0.945 o'clock whole blood viscosity all have to some extent and reduce than the model control group rat, effect and model group that small dose group lowers whole blood viscosity are more not remarkable.Prompting, liquid capsule extract of the present invention shows certain function of promoting blood circulation to disperse blood clots on non-specific pelvic inflammatory disease model.See Table 2.
Influence (X ± the S of table 2 pair pelvic inflammatory disease rat model hemorheology index; N=10)
| Group | Dosage (the g crude drug/Kg) | Whole blood viscosity (mpa.s) | Packed cell volume (%) | Blood plasma viscosity (mpa.s) | |
| 94.5 -1 | 0.945 -1 | ||||
| Dosage group small dose group in the heavy dose of group of blank group model control group JINJI JIAONANG group | --8 22.2 11.1 5.6 | 4.23±0.48 ## 5.11±0.53 4.60±0.36 * 4.01±1.45 * 4.60±.035 * 5.02±0.41 | 8.89±1.48 ## 12.67±1.55 11.36±1.32 * 9.86±1.62 ** 11.10±1.13 * 11.51±1.01 | 37.54±1.19 37.30±1.42 36.65±1.84 39.00±3.43 36.50±1.58 36.20±1.75 | 1.09±0.06 1.14±0.06 1.01±0.19 1.31±0.34 1.15±0.24 1.62±1.33 |
Annotate: T check between group: compare with the normal control group: ##P＜0.01; Compare with model control group: * P＜0.05; * P＜0.01.
2.1.2.2 influence to general form
To the observation of rat vagina collar extension as seen, as seen the vagina collar extension that played most animals after the modeling on the 3rd day has dense condensed secretions, and the activity of animal reduces.The secretions of each administration treated animal vagina collar extension after 5 days, has been compared minimizing to some extent in administration with model group.
Dissect the back perusal as seen, the normal control group: cut off peritoneum, intraperitoneal is not seen redness, and surrounding tissue is not seen significant change.The uterus color, hardness is normal, does not see hyperemia, congestion, the ovary no abnormality seen.Model group: part uterus darker in color is red, the obvious swelling of cervix uteri, hyperemia, and the slight adhesion in individual animal abdominal cavity, ovary shows no obvious abnormalities.The administration group: positive drug group, heavy dose of group, middle dosage group, small dose group are compared with model group, adhesion degree around animal abdominal cavity and metremia, swelling, intracavity exudate and tissue and the abdominal cavity all has alleviating in various degree than model group, and wherein the heavy dose of group of administration obviously alleviates.
2.1.2.3 to the morphologic influence of pathological tissue
As seen mirror is observed down:
The normal control group: endometrium does not see obviously and thickens that the intimal surface epithelium is normal or slight hypertrophy is arranged, and body of gland is not seen pathological changes, does not see obvious lymphocytic infiltration, and ovary is not seen obvious pathological changes.
Model control group: the obvious hypertrophy of endometrium, thicken, the intimal surface epithelial proliferation, karyokinesis is mutually more to be seen, between epithelial cell, the time see apoptotic body and visible more fragment.Between in the matter visible in to the severe cell infiltration, go up subcutaneous being dispersed in or kitchen range shape lymphocyte, neutrophil infiltration.Sometimes see that cell infiltration is in around the inner membrance body of gland or in the lumen of gland.Bilateral ovaries is not seen obvious pathological changes.
Positive drug control group: endometrium adenomatosis and inflammatory cell infiltration degree alleviate to some extent than model control group.Ovary is not seen obvious pathological changes.
The heavy dose of group of liquid capsule of the present invention: endometrial hyperplasia, thicken to have to a certain extent and alleviate, go up the subcutaneous slight cell infiltration that has than model group.
Dosage group in the liquid capsule of the present invention: endometrial epithelial cell has slight hypertrophy, and sample epithelial cell out of the ordinary has a small amount of apoptosis, goes up the subcutaneous cell infiltration that degree varies is arranged.
Liquid capsule small dose group of the present invention: endometrial epithelium has hypertrophy, goes up subcutaneous cell infiltration, and is more obvious individually.
According to grade scale, use SSPS software, the result that the lesion degree of uterus mucosal tissue is added up shows that model group rat uterus mucosa presents obvious pathological changes, and is remarkable with normal control group comparing difference.The lesion degree of each administration group and model group more all have to some extent and alleviate, and be remarkable with the model group comparing difference.See Table 3.
The table 3 pair influence (n=10) that non-specific pelvic inflammatory disease rat model pathological tissue changes
| Group | Dosage (the g crude drug/Kg) | The uterine mucosa lesion degree | ||||
| - | + | ++ | +++ | ++++ | ||
| Normal control group model matched group ##The JINJI JIAONANG group **Heavy dose of group **Middle dosage group **Small dose group * | 8 22.2 11.1 5.6 | 6 0 0 2 1 0 1 0 0 0 0 0 | 4 0 5 6 6 7 | 0 8 4 2 3 4 | 0 0 0 1 0 2 | 0 2 0 0 0 0 |
Annotate: rank test: compare ##P＜0.01 with the normal control group; Compare * * P＜0.01 with model group.
Grade scale: "-": rat pelvic cavity structure is normal; "+": rat pelvic cavity, uterus, ovary, vagina serosal surface are not seen obvious inflammation; " ++ "; Rat pelvic cavity, uterus, ovary, vagina serosal surface mild hyperaemia, congestion, the epithelial cell face has inflammation, vagina epithelium hypertrophy, hyperkeratosis; " +++": rat pelvic cavity, uterus, ovary, the obvious congestion of vagina upper end epithelium serosal surface, swelling, inflammatory infiltration is obvious, vagina epithelium hyperkeratosis, the obvious hypertrophy of epithelium.
2.2 influence to the nonspecific inflammation model
2.2.1 to the bullate influence of rat granuloma
[3]
Get 50 of the male rats of body weight 150-160 gram, under ether light anaesthesia condition, make abdominal incision, it is subcutaneous that the cotton balls of constant weight (30mg), sterilization has been implanted rat both sides groin, postoperative is divided into 5 groups at random, every group 10, operation this product on the same day with 22.2,11.1,5.6g/Kg dosage begins gastric infusion, administration volume 0.5ml/100g, successive administration 7 days is with the positive contrast medicine of aspirin.Put to death animal in 24 hours after the administration, peel off and take out granulation tissue, weigh after 1 hour, deduct the raw cotton ball weight, be the granuloma net weight in 60-90 ℃ of baking oven inner drying.Relatively weight between the granuloma group is calculated suppression ratio.See Table 4.
The influence of the swollen dry weight of table 4 pair rat granuloma (X ± SD)
| Group | Dosage (the g crude drug/Kg) | Granulation dry weight (mg) (%) | Suppression ratio |
| Dosage group small dose group in the heavy dose of group of model group aspirin group | 0.10 22.2 11.1 5.6 | 117.81±12.22 80.40±8.06 ** 97.25±9.36 * 97.15±9.52 * 99.88±12.37 | 46 22 21 17 |
Annotate: T check between group: compare with model control group: * P＜0.05; * P＜0.01.
2.2.2 xylol causes the influence of mice ear
[3]
Getting body weight is 25-30 gram male mice, be divided into 5 groups at random, every group 10, with liquid capsule extract 22.0 of the present invention, 11.0,5.5g/Kg gastric infusion is 3 days continuously, the dosage of positive drug aspirin is 0.1g/Kg, after the last administration 1 hour, dimethylbenzene 0.1ml is dripped two sides, front and back in mouse right ear with sample injector, left ear is contrast, 0.5 put to death mice after hour, cut two ears along the auricle baseline, lay round auricle at same position respectively, organize balance to weigh with the card punch of 8mm diameter, deduct left auricle with the auris dextra of every Mus and heavily be the swelling degree, calculate average and the standard deviation of respectively organizing the swelling degree, calculate its suppression ratio, the comparable group differences.
The result shows that this product 26.0,13.0,5.7g/Kg dosage all can suppress the ear swelling of mice caused by dimethylbenzene xylene, and prompting this product has inhibitory action definitely to the non-specific acute inflammation model of mice.See Table 5.
Table 5, to the influence (X ± S of mice ear; N=10)
| Group | Dosage (the g crude drug/kg) | Swelling degree (mg) | Suppression ratio % |
| Dosage group small dose group in the heavy dose of group of model group aspirin group | 0.10 26.0 13.0 6.5 | 20.10±4.78 11.31±3.28 ** 13.18±2.19 ** 13.70±3.71 ** 15.06±5.48 * | 77.70 53.49 44.65 25.07 |
Annotate: T check between group: compare with model control group: * P＜0.05; * P＜0.01.
3, conclusion
3.1 the result of the test of two kinds of pelvic inflammatory disease models shows, the medicine that makes by technical solution of the present invention can suppress due to the escherichia coli the non-special pelvic inflammatory disease model of rat due to the rat specificity pelvic inflammatory disease model and phenol paste, the cell infiltration and the pathologic thereof that suppress rat vagina and Uterine mucosa tissue change, and reduce its blood viscosity.Point out it that pelvic inflammatory disease model due to antibacterial and the non-bacterial infection is had therapeutical effect definitely.
3.2 the result of the test of two kinds of nonspecific inflammation models shows, the medicine that makes by technical solution of the present invention can suppress dimethylbenzene induced mice ear swelling and rat granuloma is swollen.Point out it inhibited, and effect has met or exceeded the product that former process makes to the nonspecific inflammation model.
Claims (7)
1, a kind of liquid capsule for the treatment of gynecological inflammation is characterized in that: be made up of by following weight proportion Chinese medical concrete powder, suspending agent and dispersant: 1: 0.05-0.15: 0.7-2.0; Described Chinese medical concrete powder is by Caulis Spatholobi, Radix Rosae Laevigatae, Radix Flemingiae Philippinensis, Caulis Mahoniae, Radix Zanthoxyli and Herba Andrographis by weight: 30: 16: 16: make at 16: 6: 5.
2, liquid capsule of treatment gynecological inflammation according to claim 1 and preparation method thereof is characterized in that: described suspending agent can be one or more the mixture in Cera Flava, lecithin, aluminum monostearate, the ethyl cellulose.
3, the liquid capsule of treatment gynecological inflammation according to claim 1 and 2 is characterized in that: described dispersant vegetable oil can be one or more the mixture in soybean oil, Oleum sesami, Oleum Arachidis hypogaeae semen, Oleum Brassicae campestris and other edible plants oil.
4, the liquid capsule of treatment gynecological inflammation according to claim 1 and 2 is characterized in that: described suspending agent is a Cera Flava, and described dispersant is a soybean oil.
5, the liquid capsule of treatment gynecological inflammation according to claim 5 is characterized in that: described Chinese medical concrete powder: Cera Flava: the soybean oil weight ratio is 1: 0.1: 1.4.
6, the liquid capsule of treatment gynecological inflammation according to claim 1 and 2 is characterized in that: made by following preparation method: a. gets Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 60%～80% ethanol of 6～10 times of amounts, extracts 2～3 times, each 1～2 hour, filter, merging filtrate reclaims ethanol, filter filtrate for later use; B. get Radix Rosae Laevigatae and Radix Flemingiae Philippinensis, add 6～10 times of water gagings, decoct 2～3 times, each 1～2 hour, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, relative density is 1.10～1.20 extractum when continuing to be concentrated into 60 ℃; D. with extract dry among the c, make fine powder, e. gets suspending agent, dispersant, and 60-70 ℃ of heat fused adds above-mentioned medicated powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
7, the liquid capsule of treatment gynecological inflammation according to claim 1 and 2, it is characterized in that: a. gets Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Zanthoxyli adds 70% ethanol of 8 times of amounts, extract three times, each 2 hours, filter merging filtrate, reclaim ethanol to there not being the alcohol flavor, leave standstill, filter filtrate for later use; B. get Radix Rosae Laevigatae, Radix Flemingiae Philippinensis adds 8 times of water gagings, decocts secondary, and each 2 hours, collecting decoction filtered, and filtrate is condensed into extractum; C. filtrate among extractum among the b and a is merged, mixing, relative density is 1.15～1.20 extractum when continuing to be concentrated into 60 ℃; D. extractum among the c is spray dried to fine powder; E. get 1 part of above-mentioned dried cream powder, 0.1 part of suspending agent, 1.4 parts of dispersants, suspending agent, dispersant 60-70 ℃ heat fused adds dried cream powder, and mixing is made suspension, and 60-70 ℃ of insulation made liquid capsule with the liquid capsule filling machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101205550A CN1823973B (en) | 2005-12-27 | 2005-12-27 | Liquid capsule for treating gynecophthy inflammation and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101205550A CN1823973B (en) | 2005-12-27 | 2005-12-27 | Liquid capsule for treating gynecophthy inflammation and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823973A true CN1823973A (en) | 2006-08-30 |
| CN1823973B CN1823973B (en) | 2012-01-11 |
Family
ID=36934913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005101205550A Expired - Fee Related CN1823973B (en) | 2005-12-27 | 2005-12-27 | Liquid capsule for treating gynecophthy inflammation and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1823973B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218046A (en) * | 2011-06-14 | 2011-10-19 | 贵州地道药业有限公司 | Chinese patent medicine soft capsule ingredients-mixing technology |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100375617C (en) * | 2003-07-22 | 2008-03-19 | 范敏华 | Liquid capsule and production method thereof |
| CN1628765A (en) * | 2004-08-19 | 2005-06-22 | 贵阳云岩西创药物科技开发有限公司 | Cherokee rose root formulation for treating gynecological disease and its preparation process |
-
2005
- 2005-12-27 CN CN2005101205550A patent/CN1823973B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102218046A (en) * | 2011-06-14 | 2011-10-19 | 贵州地道药业有限公司 | Chinese patent medicine soft capsule ingredients-mixing technology |
| CN102218046B (en) * | 2011-06-14 | 2012-03-14 | 贵州地道药业有限公司 | Chinese patent medicine soft capsule ingredients-mixing technology |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1823973B (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN101036703A (en) | Method for preparing Chinese traditional medicine combination for curing gynecopathy | |
| CN1823973A (en) | Liquid capsule for treating gynecophthy inflammation and its preparation method | |
| CN1895458A (en) | Compound Chinese-medicinal extract for treating gynaopathy and its preparation | |
| CN1824077A (en) | Chinese medicinal liquid capsule for treating gynecopathy and its preparation method | |
| CN1628771A (en) | Lotion for treating gynecological disease and its preparation process | |
| CN1682969A (en) | Medicinal composition and its preparing method and quality control method | |
| CN1318055C (en) | Method for preparing medicine | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN101045105B (en) | Method for preparing traditional Chinese medicine composition for treating gynaopathy | |
| CN1823980A (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1781526A (en) | Method for preparing medicine | |
| CN1739656A (en) | Prepn process of medicine for treating gynecopathy | |
| CN1785417A (en) | Chinese medicinal preparation for treating gynecopathy inflammation and its preparing process | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN1785392A (en) | Chinese medicinal composition for treating prostatitis and its preparation method | |
| CN1316980C (en) | Medicinal use of spanish moss of Chinese traditional medicine | |
| CN1291738C (en) | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same | |
| CN1650950A (en) | Traditional Chinese medicine for treating cow endo metritis | |
| CN101045112A (en) | Method for preparing traditional Chinese medicine composition to treat gynaopathy | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1533799A (en) | Chinese medicinal tablet for treating gynecopathy and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120111 Termination date: 20141227 |
|
| EXPY | Termination of patent right or utility model |